Actively Recruiting
Phase 1b2 Study of Trastuzumab Deruxtecan Alone or with Chemotherapy and Immunotherapy in Adults with Advanced HER2-Expressing Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Led by AstraZeneca · Updated on 2026-07-10
450
Participants Needed
100
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the safety, tolerability, how the body processes, immune response, and early anti-tumor effects of trastuzumab deruxtecan T-DXd alone or combined with chemotherapy andor immunotherapy. This study focuses on adults with HER2-expressing advanced or metastatic gastric, gastroesophageal junction GEJ, and esophageal adenocarcinoma who have either not been treated before for advanced disease or have progressed after prior trastuzumab treatment. The trial aims to find manageable safety profiles and preliminary evidence of anti-tumor activity to support further testing.
CONDITIONS
Brief Title
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
